Sunovion Announces Results From Its Open-Label Extension Study Of Schizophrenia Treatment

Sunovion Pharmaceuticals Inc. (Sunovion) announced results from study SEP361-202, which evaluated the long-term safety and effectiveness of SEP-363856, a novel non-dopamine 2 agent under investigation for the treatment of individuals with schizophrenia. The results of study SEP361-202, the open-label extension study of the four-week, double-blind, placebo-controlled study SEP361-201, were presented at the 58th Annual Meeting of the American College of Neuropsychopharmacology in Orlando, Florida.

The study results were presented as a poster titled “Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study . . .